VAXIMM

DGAP-News: NEC OncoImmunity Acquires VAXIMM's Neoantigen Vaccine Development Assets

Retrieved on: 
Tuesday, March 8, 2022
NEC, Patient, Artificial intelligence, CMS, Vaccine, Immunotherapy, Cancer, Contract, Biotechnology, DNA, CTO, Safety, Infection, HLA, LinkedIn, Program, Board, Efficiency, Company, CSV, Acquisition, Trial of the century, CEO, Clinical trial, Glioblastoma, AI, Technology, MD, NOI, Health, Brain, Antigen presentation, Descriptive ethics, Algorithm, Pharmaceutical industry, Medical device, VAXIMM, NEC Corporation, NEC OncoImmunity AS, NEC's AI Drug Development Business, NEC's Neoantigen Prediction System, VAXIMM, NEC Corporation, NEC OncoImmunity AS, NEC's AI Drug Development Business, NEC's Neoantigen Prediction System, VAXIMM, NEC CORPORATION, NEC ONCOIMMUNITY AS, NEC'S AI DRUG DEVELOPMENT BUSINESS, NEC'S NEOANTIGEN PREDICTION SYSTEM

Dr. Heinz Lubenau, CEO and Co-founder of VAXIMM, said, "We believe that NEC OncoImmunity is the ideal company to take VAXIMM's novel neoantigen programs through development and hopefully to the market to help patients.

Key Points: 
  • Dr. Heinz Lubenau, CEO and Co-founder of VAXIMM, said, "We believe that NEC OncoImmunity is the ideal company to take VAXIMM's novel neoantigen programs through development and hopefully to the market to help patients.
  • VAXIMM has recently licensed its neoantigen program assets to NEC OncoImmunity, a subsidiary of NEC Corporation.
  • NEC's neoantigen prediction system utilizes its proprietary AI, such as graph-based relational learning, trained on multiple sources of biological data to discover candidate neoantigen targets.
  • With NEC OncoImmunity now onboard, NEC continues to strengthen its top class neoantigen prediction pipelines with the aim of maximizing the therapeutic benefits of personalized cancer immunotherapy for patients worldwide.

DGAP-News: VAXIMM Announces First Results from Phase I/II Trial in Progressive Glioblastoma with Oral T-cell Immunotherapy VXM01 in Combination with PD-L1 Inhibitor Avelumab to be Presented at ASCO20 Virtual

Retrieved on: 
Thursday, May 14, 2020
Health, Medicine, Clinical medicine, Avelumab, Breakthrough therapy, Merck, PD-L1, Oncology, Glioblastoma, VXM01, VAXIMM

The presentation, entitled, "Oral DNA vaccination targeting VEGFR2 combined with anti-PD-L1 avelumab in patients with progressive glioblastoma: Safety run-in results-NCT03750071," will be given as part of the Developmental Therapeutics - Immunotherapy Oral Session.

Key Points: 
  • The presentation, entitled, "Oral DNA vaccination targeting VEGFR2 combined with anti-PD-L1 avelumab in patients with progressive glioblastoma: Safety run-in results-NCT03750071," will be given as part of the Developmental Therapeutics - Immunotherapy Oral Session.
  • Secondary endpoints include objective response rate (ORR), clinical response using immune-response assessment in neuro-oncology (iRANO) criteria and immunological assays.
  • Nine patients treated with VXM01 and avelumab in 2 dose groups had completed the safety run-in phase.
  • Three partial responses according to iRANO criteria with tumor reductions of 58, 81 and 95% to baseline were reported.